Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Jul;87(1):e8-e11.
doi: 10.1016/j.jinf.2023.04.015. Epub 2023 Apr 24.

Risk of severe outcomes among SARS-CoV-2 Omicron BA.4 and BA.5 cases compared to BA.2 cases in England

Nurin Abdul Aziz  1 , Sophie Grace Nash  2 , Asad Zaidi  2 , Tommy Nyberg  3 , Natalie Groves  4 , Russell Hope  5 , Jamie Lopez Bernal  6 , Gavin Dabrera  2 , Simon Thelwall  7
Affiliations
Case Reports

Risk of severe outcomes among SARS-CoV-2 Omicron BA.4 and BA.5 cases compared to BA.2 cases in England

Nurin Abdul Aziz et al. J Infect. 2023 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest GD declares that his employer’s predecessor organisation, Public Health England, received funding from GlaxoSmithKline for a research project related to influenza antiviral treatment. This preceded and had no relation to COVID-19, and GD had no role in and received no funding from the project. All other authors report no potential conflicts.

Figures

Fig. 1
Fig. 1
(A) Incidence of all confirmed COVID-19 Omicron BA.2, BA.4, and BA.5 in England between 1 April 2022 and 1 August 2022. (B) Incidence of individuals with BA.2, BA.4, and BA.5 included in the analysis by outcome status, according to outcome definition 1 where cases are individuals admitted ≥ 2 days or died within 2 days of attending ED and controls are individuals discharged from ED or admitted for< 2 days.
See this image and copyright information in PMC

References

    1. Kang SW, Park H, Kim JY, Lim SY, Lee S, Bae JY, et al. Comparison of the clinical and virological characteristics of SARS-CoV-2 Omicron BA.1/BA.2 and omicron BA.5 variants: a prospective cohort study. J Infect [Internet]; 2023 Jan 16 [cited 2023 Mar 3]. Available from: 〈https://www.journalofinfection.com/article/S0163-4453(23)00020-8/fulltext〉. - PMC - PubMed
    1. Wang Q., Guo Y., Iketani S., Nair M.S., Li Z., Mohri H., et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature. 2022;608(7923):603–608. - PMC - PubMed
    1. Phua J., Weng L., Ling L., Egi M., Lim C.M., Divatia J.V., et al. Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. Lancet Respir Med. 2020;8(5):506–517. - PMC - PubMed
    1. Davies MA, Morden E, Rosseau P, Arendse J, Bam JL, Boloko L, et al. Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa. medRxiv; 2022, 2022.06.28.22276983. - PMC - PubMed
    1. Wolter N., Jassat W., Walaza S., Welch R., Moultrie H., Groome M.J., et al. Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa. Nat Commun. 2022;13(1):5860. - PMC - PubMed